Publication date: Jul 08, 2019
Frequent administration of gadolinium-based contrast agents in multiple sclerosis (MS) may increase signal intensity (SI) unenhanced T1-weighted imaging MRI throughout the brain. We evaluated the association between lifetime cumulative doses of gadodiamide administration and increased SI within the dentate nucleus (DN), globus pallidus (GP), and thalamus in patients with early MS.
A total of 203 patients with MS (107 with baseline and follow-up MRI assessments) and 262 age- and sex-matched controls were included in this retrospective, longitudinal, 3T MRI-reader-blinded study. Patients with MS had disease duration
Zivadinov, R., Bergsland, N., Hagemeier, J., Ramasamy, D.P., Dwyer, M.G., Schweser, F., Kolb, C., Weinstock-Guttman, B., and Hojnacki, D. Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS. 18542. 2019 Neurology.
- Gadolinium deposition occurs in early multiple sclerosis
- Gadolinium Retention in the Brain: An MRI Relaxometry Study of Linear and Macrocyclic Gadolinium-Based Contrast Agents in Multiple Sclerosis.